Kyverna Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and related conditions
The company specializes in harnessing the power of engineered immune cells to create transformative treatment options. By utilizing advanced genetic engineering techniques, Kyverna aims to target and modify the immune system's response, thereby addressing the underlying causes of autoimmune disorders. Through its research and development initiatives, the company strives to deliver novel, effective solutions that improve patient outcomes and enhance quality of life for those affected by these challenging diseases.
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune disease patients but faces challenges in cost and manufacturing.
Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. Here's a look at the details:
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.
